Security key
00182C103
ANI PHARMACEUTICALS INC - Common Stock (ANIP)
CUSIP: 00182C103
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 343
- Total 13F value
- $28,394
- Share change
- +14
- SEC-reported price per share
- $82.78
- Number of holders
- 2
- Value change
- +$1,159
- Number of buys
- 1
- Shares outstanding
- 22,278,088
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
2
Top holders
2
ANIP full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
ANI PHARMACEUTICALS INC SEC filings
ANI PHARMACEUTICALS INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00182C103
Recent filing periods:
Ownership snapshot
Top reported holders of ANIP - ANI PHARMACEUTICALS INC - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
15/15
Latest evidence
12 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 11%
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 11%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
11%
Meridian Venture Partners II GP, ...
4.8%
MILLENNIUM MANAGEMENT LLC
3.8%
INTEGRATED CORE STRATEGIES (US) LLC
0.3%
Muthusamy Shanmugam
2.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
Company
|
11%
|
$230,596,038
2,517,424 shares
|
$0 | 30 Sep 2025 |
| Meridian Venture Partners II GP, L.P. |
13D/G
Robert E. Brown, Jr.
|
4.8%
|
$66,419,394
1,034,570 shares
|
-$9,630,000 | 21 Aug 2025 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
3.8%
|
$57,136,569
818,341 shares
|
-$19,037,261 | 31 Mar 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
Millennium Management LLC
|
0.3%
|
$5,976,442
65,245 shares
|
-$96,309,614 | 30 Sep 2025 |
| Muthusamy Shanmugam |
3/4/5
HEAD OF R&D, COO-NOVITIUM OPS, Director
|
2.4%
|
$44,650,672
537,976 shares
|
-$17,860,541 | 26 Feb 2026 |
| Nikhil Lalwani |
3/4/5
PRESIDENT & CEO, Director
|
1.6%
|
$27,140,889
349,889 shares
|
-$9,160,923 | 11 May 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
343
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
277
Q2 2026 holders
2
Holder diff
-275
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend